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Abstract
Background: The clinical, radiological and pathological similarities between sarcoidosis and tuberculosis can make disease
differentiation challenging. A complicating factor is that some cases of sarcoidosis may be initiated by mycobacteria. We
hypothesised that immunological profiling might provide insight into a possible relationship between the diseases or allow
us to distinguish between them.
Methods: We analysed bronchoalveolar lavage (BAL) fluid in sarcoidosis (n = 18), tuberculosis (n = 12) and healthy
volunteers (n = 16). We further investigated serum samples in the same groups; sarcoidosis (n = 40), tuberculosis (n = 15) and
healthy volunteers (n = 40). A cross-sectional analysis of multiple cytokine profiles was performed and data used to
discriminate between samples.
Results: We found that BAL profiles were indistinguishable between both diseases and significantly different from healthy
volunteers. In sera, tuberculosis patients had significantly lower levels of the Th2 cytokine interleukin-4 (IL-4) than those
with sarcoidosis (p = 0.004). Additional serum differences allowed us to create a linear regression model for disease
differentiation (within-sample accuracy 91%, cross-validation accuracy 73%).
Conclusions: These data warrant replication in independent cohorts to further develop and validate a serum cytokine
signature that may be able to distinguish sarcoidosis from tuberculosis. Systemic Th2 cytokine differences between
sarcoidosis and tuberculosis may also underly different disease outcomes to similar respiratory stimuli.
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Introduction
There are numerous anecdotal case reports of patients with
shared respiratory exposures who subsequently develop different
diseases. One such intriguing study involves monozygotic twins.
One twin presented with dyspneoa, a pleural effusion, strongly
positive Mantoux and negative Kveim test, and subsequently
responded appropriately to anti-tuberculous therapy. The other
twin denied respiratory symptoms but a chest radiograph revealed
bilateral hilar lymphadenopathy, a Kveim test was positive and the
clinical course was in keeping with sarcoidosis [1].
Mycobacterial involvement in sarcoidosis pathogenesis remains
a contentious issue. Supporting evidence includes similarities in
clinical and radiographic picture [2], identification of mycobac-
terial DNA in sarcoid granulomas [3] and the finding in some
sarcoidosis cohorts of peripheral blood and bronchoalveolar lavage
(BAL) INFc-mediated T-cell responses towards a mycobacterial
proteins such as KatG [4]. Conversely, evidence against a
relationship includes the marked differences in extra-pulmonary
disease sites and treatment strategy [2], and the absence of INFc-
mediated T-cell responses towards the immunodominant myco-
bacterial proteins ESAT-6 and CFP-10 in large worldwide
sarcoidosis studies [5–7].
The T-cell profile in sarcoidosis BAL cells is biased towards Th1
cytokines [8] with similar findings in tuberculosis [9]. This picture
is distinct from that seen in atopic asthma which exhibits a Th2
bias [10] or hypersensitivity pneumonitis which displays a strong
Th17 response [11]. In contrast to BAL, there are few studies of
serum cytokine profile in either disease.
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Multiplexed protein analysis is increasingly used for immune
profiling and biomarker identification where accurate rapid
diagnosis is paramount [12] with promising data in a number of
diseases including Systemic Lupus Erythematosus [13] and
prostate cancer [14].
Analysis of cytokine profiles in demographically matched
patients with sarcoidosis and tuberculosis may provide further
insights into any relationship between both diseases or allow
identification of diagnostic signatures. We therefore decided to
investigate unstimulated BAL and serum samples in pulmonary
sarcoidosis, pulmonary tuberculosis and healthy controls by
measuring a cytokine panel which best represented the spectrum
of immune process involved in both diseases including the Th1
(INFc, TNFa) vs Th2 (IL-4, IL-5, IL-13) balance, T-cell
stimulation (IL-2, IL-12), macrophage activation (Il-1b), granulo-
ma formation (IL-8), and limitation of inflammation (IL-10). We
believe that the data detailed here has achieved these aims and
opens the avenue towards further work to identify serum cytokine
signatures to distinguish between both diseases.
Methods
Ethics Statement
All participants were recruited after providing written informed
consent and ethical permission for the study was obtained by the
St. Mary’s Ethics Committee (reference 07/H0712/85).
Patients and Controls
All patients with tuberculosis or sarcoidosis had pulmonary
disease with evidence of additional extra-pulmonary involvement
in a minority of cases. Tuberculosis samples were taken from
culture confirmed cases. Sarcoidosis samples were taken from
patients with a strong clinical diagnosis, supportive histology and a
subsequent clinical course in keeping with the original diagnosis as
per American Thoracic Society guidelines [15]. Tuberculosis and
sarcoidosis samples were taken from St. Mary’s Hospital London
and The Royal Brompton Hospital London, and matched to the
extent possible for age, sex and ethnicity. All diseased BAL
samples were taken prior to starting any treatment. Sarcoidosis
serum samples were taken from patients on minimal steroid
therapy (#10 mg prednisolone daily) and on no other immuno-
supressants. Healthy volunteer samples were taken from two
unrelated studies within the Centre for Respiratory Infection,
Imperial College. All healthy volunteers were recruited from
London. They were not specifically screened for latent tuberculosis
disease (with either IGRA or Tuberculin Skin Testing) but they
had no evidence of respiratory disease and no other significant co-
morbidities. All samples were collected over a 24 month period.
Demographic data for all individuals is displayed in table 1.
Sample Processing
Processing occurred under category 2 containment conditions.
BAL fluid was collected using standard guidelines at Imperial
College NHS Trust after instilling approximately 90 ml of 0.9%
saline into the airways with return of approximately 40 ml. The
fluid was then passed through a 100 mm aperture mesh. Serum
was processed from blood which was allowed to clot for 60 mins
before centrifuging at 1000 g for 10 mins at room temperature
(RT). All samples were stored at 280uC within 90 mins of
collection.
Multiplex Cytokine Analysis
Multiplex cytokine analysis was performed in precoated 96 well
plates (Human TH1/TH2 10 plex ultrasensitive assay, Meso Scale
Discovery – MSD, Maryland, USA). 25 microL of diluent 2 was
dispersed into each well. The plate was sealed and incubated by
vigorous horizontal shaking for 30 minutes at RT. 25 microL of
the sample (BAL fluid, serum or internal standard) was added per
well and all samples measured in duplicate. Plates were sealed and
incubated by vigorous horizontal shaking for two hours at RT.
Plates were washed three times with 0.05% Tween 20 (Abcam,
Cambridge, UK) in PBS (Sigma-Aldrich, UK). 25 microL of 16
detection antibody solution was placed per well and sealed plates
were incubated by vigorous horizontal shaking for two hours at
RT. Plates were washed three times with 0.05% Tween 20 in PBS.
150 microL of 26Read Buffer T was added to each well. Plates
were analysed using the MSD SECTOR Imager 2400 and
Discovery Workbench 3.0 software (both from Meso Scale
Discovery, USA). The mean value of two wells was taken as the
recorded reading, provided that the coefficient of variation (CV)
was less than 10%. Concentrations recorded lower than the
standard curve were kept as absolute values. For purposes of
logarithmic analysis, readings of 0 were adjusted to 0.01 pg/ml.
Statistical Analysis
For each direct comparison (sarcoidosis vs. tuberculosis,
sarcoidosis vs. healthy and tuberculosis vs. healthy) a p-value
was calculated using a Mann-Whitney test for each cytokine. P-
values were adjusted for multiple comparisons using a Bonferroni
correction (multiplying each p-value by 10). Data analysis was
performed using GraphPad Prism version 5.04 for Macintosh (La
Jolla, California, USA). To create a classification rule to
distinguish between diseases, partial least squares (PLS) logistic
regression was carried out using the gpls package in R version
2.13.1 (R Foundation for Statistical Computing, Vienna, Austria).
The within sample mis-classification rate was calculated for the
logistic regression model found by PLS. Leave-one-out cross-
validation was used to obtain an estimate of prediction error of the
PLS logistic regression model.
Results
The BAL Cytokine Profile in Acute Pulmonary Sarcoidosis
is Indistinguishable from Active Pulmonary Tuberculosis
The cytokine profiles in acute pulmonary sarcoidosis and active
pulmonary tuberculosis BAL (all from untreated patients within 2
weeks of diagnosis) were indistinguishable from each other (Table 2
and Figure 1a). The median levels of the Th1 cytokines INFc and
TNFa were higher in both diseases compared to healthy BALs and
this elevation was significant (p , 0.05) with TNFa (Figure 1b).
Median BAL levels of the Th2 cytokines IL-4 and IL-13
(Figure 1c) were significantly higher in sarcoidosis and tuberculosis
compared to healthy BALs (p , 0.001). Raised IL-5 levels were
found in diseased BALs compared to healthy but this increase
reached statistical significance in tuberculosis only. Levels of IL-1b
and IL-10 were significantly elevated in both diseases compared to
healthy BALs, whereas levels of IL-2 were significantly increased
in sarcoidosis only. Levels of IL-12p70 and IL-8 were not
significantly different between any group.
Serum IL-4 Levels are Significantly Lower in Pulmonary
Tuberculosis Compared to Pulmonary Sarcoidosis
Serum levels of the Th1 cytokines INFc and TNFa were
significantly elevated in both pulmonary sarcoidosis and pulmo-
nary tuberculosis compared to healthy volunteers (Table 2 and
Figure 2a). Levels of IL-2 and IL-8 were elevated in both diseases
compared to healthy volunteers but these increases only reached
statistical significance in sarcoidosis. Lower levels of IL-1b were
Sarcoidosis and Tuberculosis Cytokine Profiles
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e38083
detected in both diseases compared to healthy serum with
significance in sarcoidosis and just below significance in tubercu-
losis (adjusted p= 0.059). Serum levels of IL12p70 and IL-10 were
not significantly different between any group.
In contrast, levels of serum Th2 cytokines IL-4, IL-5 and IL-13
were reduced in both diseases compared to the healthy volunteers.
Importantly, serum levels of IL-4 were significantly lower
(p = 0.004) in tuberculosis compared to sarcoidosis (Figure 2b)
and these differences remained when comparing patients with
acute pulmonary sarcoidosis and active pulmonary tuberculosis
only, all of whom were recruited prior to the start of appropriate
treatment (Figure 2c). Levels of IL-5 and IL-13 were also lower in
tuberculosis although these differences did not reach statistical
significance. On detailed analysis of pulmonary sarcoidosis sera,
no significant differences were observed in any measured cytokine
with regards to presence of pulmonary fibrosis, presence of extra-
pulmonary disease or length of time since diagnosis (data not
shown).
Differences in Serum Cytokine Profile Allow for
Differentiation between Pulmonary Sarcoidosis and
Pulmonary Tuberculosis
A targeted bioinformatic approach to exploit the serum cytokine
differences was employed to differentiate between sarcoidosis and
tuberculosis. Partial least squares was used to create a logistic
regression model comparing the values of all serum cytokines. The
best fit model found was log(P(Tuberculosis)/P(sarcoidosis))
= 1.214 + 8.884 * IL1 + 0.075 * IFN + 0.32 * IL12p70 + 0.039
* TNF 2 0.097 * IL5 2 0.015 * IL8 2 0.73 * IL13 2 0.606 *
IL10 2 2.404 * IL2 2 4.231 * IL4. The classification rule was to
classify a sample as tuberculosis if log(P(tuberculosis)/P(sarcoido-
sis)) was greater than zero, or as sarcoidosis otherwise.
By applying this model to the data, the observed and predicted
disease groups for the sera were recorded (Figure 3). The created
model had a within-sample mis-classifcation rate of 9% (5/55 sera)
i.e. allowed prediction of whether a serum sample was sarcoidosis
or tuberculosis with 91% accuracy. The within-sample error rate is
possibly an under-estimate of the true prediction error of this
model, as the same data were used both to fit the model and assess
its accuracy. Leave-one-out analysis was therefore performed for
cross validation and used to obtain a better estimate of prediction
error which was 27% (15/55).
Compartmentalisation of Cytokines between BAL and
Serum in Sarcoidosis is Similar to that Seen in
Tuberculosis
The compartmentalisation of cytokines between BAL and
serum (in terms of where the higher concentration was found)
was similar in acute pulmonary sarcoidosis and active pulmonary
tuberculosis for all 10 cytokines measured (Figure 4a). With Th2
cytokines, differences were apparent when compared to the
healthy groups e.g. median levels of IL-4 were higher in BAL than
serum in both sarcoidosis (ratio of BAL: serum=5.39) and
tuberculosis (ratio = 2.01) but this pattern was reversed in healthy
volunteers where almost no IL-4 was measured in the BAL giving
a ratio of less than 1 (Figures 4b-d). The patterns seen were also
observed where data was available within the same patients as
shown in figure 4e e.g. 11 of 14 sarcoidosis patients had
significantly higher levels of IL-4 in their BAL than their serum
(p= 0.0062).
Discussion
This is the first study to compare cytokine profiles both
peripherally and at the site of disease in patients with sarcoidosis
and tuberculosis. Acute pulmonary sarcoidosis and active pulmo-
nary tuberculosis share a number of clinical, radiological and
histological similarities making differential diagnosis difficult. We
have shown that cytokine profiles in the BAL of both diseases
appear indistinguishable from each other but that differences exist
in serum. With respect to BAL, significantly elevated TNFa
(compared to healthy volunteers) was expected from previous
studies [16], [17] but is shown here for the first time to be at
similar levels in demographically matched patients. This may
represent a general acute phase response not seen in healthy lungs.
However, TNFa has a number of specific functions including
activation of macrophages and granuloma formation [18] and the
indistinguishable BAL levels indicate that the host TNFa response
Table 1. Demographic and clinical characteristics of patients with pulmonary sarcoidosis, pulmonary tuberculosis, and healthy
volunteers.
Pulmonary sarcoidosis Pulmonary tuberculosis Healthy volunteers
Bal study population
Number 18 12 16
Pulmonary disease only (%) 16 (89) 11 (92) N/A
Median age (range) 47.5 (27–72) 39 (24–77) 27 (18–42)
Female gender (%) 8 (44) 6 (50) 10 (63)
Ethnic origin: Caucasian/Indian subcontinent/Black 9/2/7 6/3/3 15/0/1
Time since diagnosis 0–2 weeks 0–2 weeks N/A
Serum study population
Number 40 15 40
Pulmonary disease only (%) 29 (73) 11 (73) N/A
Median age (range) 48 (27–73) 33 (25–71) 31 (20–60)
Female gender (%) 21 (53) 5 (33) 26 (65)
Ethnic origin: Caucasian/Indian subcontinent/Black 19/8/13 4/10/1 33/4/3
Time since diagnosis 0–5 years 0–2 weeks N/A
doi:10.1371/journal.pone.0038083.t001
Sarcoidosis and Tuberculosis Cytokine Profiles
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Figure 1. Cytokine profiles in the BAL of pulmonary sarcoidosis, pulmonary tuberculosis and health volunteers. (A) BAL cytokine
profile, (B) BAL levels of TNFa and (C) BAL levels of IL-13.
doi:10.1371/journal.pone.0038083.g001
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at site of disease is similar in both conditions, regardless of the
diagnosis and etiology.
The Th2 cytokines IL-4 and IL-13 were significantly raised in
both diseases compared to healthy control BALs. To date,
sarcoidosis BAL T-cell studies have been inconsistent with regard
to Th2 cytokines. One study found levels of spontaneous IL-4
secretion similar to healthy controls [19] while another found
mRNA expression of IL-13 was significantly increased compared
to healthy controls [20] in keeping with our data. With regards to
tuberculosis, we are unaware of previous work investigating IL-13
BAL levels but increased IL-4 secretion from both CD4+ and
CD8+ T-cells in active pulmonary tuberculosis has been shown
compared to those with latent infection [21]. Elevated Th2 BAL
levels seen here also resulted in disease-specific compartmental-
isation with levels of IL-4, IL-5 and IL-13 higher in the BAL than
the serum, the opposite pattern to that seen in healthy controls.
The serum cytokine data indicate for the first time an identical
Th1 cytokine pattern (as demonstrated by INFc and TNFa) in
both diseases, significantly elevated over healthy volunteers. There
is limited published data on serum cytokine profiles in either
disease but tuberculosis studies have found an elevated serum
INFc compared to healthy controls [22]. A major finding of our
study is that serum levels of IL-4 were significantly lower in
tuberculosis, compared with sarcoidosis. This difference remained
after statistical bonferroni correction for multiple comparisons.
The five tuberculosis patients with measurable IL-4 did not differ
clinically or radiographically as a group compared to the majority
with undetectable levels.
These serum differences allowed for the creation of a logistic
regression model to differentiate between both diseases with 91%
accuracy. Of the five patients misclassified by the model, there
were no clinical features that would separate them from the
correctly classified patients. Leave one out analysis was performed
to cross validate our model and assess the accuracy in an
independent data set and this resulted in an accuracy of 73%,
perhaps representing a more accurate level of discrimination in
clinical practice. A recent transcriptomic study revealed a
sarcoidosis blood signature which could not be differentiated from
tuberculosis [23]. Transcriptomic whole blood signatures do not
necessarily correlate with serum protein levels and alternative
methods of investigation, such as in the case of our study, may
provide better indicators of serum cytokine activity.
One previous study has quantified mRNA levels of IL-4 in
sarcoidosis and tuberculosis granulomas within diseased lymph
nodes and found that four out of eight tuberculosis samples
expressed detectable amounts of IL-4 and/or IL-5 mRNA,
compared with undetectable levels in six sarcoidosis samples
[24]. One explanation for this is that Th2 cells may localize to the
site of disease in tuberculosis but not so in sarcoidosis, leading to
the higher serum IL-4 levels found in our sarcoidosis patients. It is
known that both diseases tend to have predominantly Th1 cells at
the site of disease [8,9] but there is currently limited published
evidence for the theory that there is a difference in localization of
Th2 cells between diseases. Another study showed that the
intracellular IL-4 content of peripheral blood lymphocytes was
diminished in patients with pulmonary tuberculosis compared to
healthy volunteers [25] and a selective increase in mRNA of the
IL-4 antagonist IL-4d2 in peripheral cells has been identified in
latent tuberculosis infection compared to healthy controls [26].
Both of these peripheral blood studies are consistent with our
finding of very low levels of serum IL-4 in the majority of patients
with pulmonary tuberculosis.
A possible explanation for the similarities in BAL but differences
in serum cytokine profiles is that both sarcoidosis and tuberculosis
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Figure 2. Serum cytokine profiles in sarcoidosis, tuberculosis and healthy volunteers. (A) Serum cytokine profile and (B) serum levels of IL-
4 in pulmonary sarcoidosis, pulmonary tuberculosis and healthy volunteers; and (C) serum levels of IL-4 in acute pulmonary sarcoidosis, active
pulmonary tuberculosis and healthy volunteers.
doi:10.1371/journal.pone.0038083.g002
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share similar infectious triggers leading to the identical granulo-
matous-type host immune responses in the lungs. This is supported
by indistinguishable levels of all cytokines measured in the BAL
spanning the spectrum of pathogen response including T-cell
stimulation (IL-2, IL-12), macrophage activation (IL-1b) and
granuloma formation (TNFa, IL-8). However, despite similar local
responses at the site of disease, the systemic response varies
between individuals as evidenced by significantly higher serum IL-
4 levels (and the possible elevation of IL-5 and IL-13) in
sarcoidosis. The increased serum IL-4 levels in sarcoidosis may
reflect a persistent and ongoing multi-system inflammatory allergic
type response to an antigen not completely cleared by the immune
system, in contrast to the lower levels seen in tuberculosis.
Importantly, there was no difference in incidence of asthma or
COPD between the sarcoidosis and tuberculosis groups so this is
not responsible for the differences seen in serum Th2 profiles.
A number of diseases of abnormal host immunity such as
chronic graft vs host disease [27] and systemic sclerosis [28] are
characterised by Th2 cells secreting IL-4 which subsequently plays
a role in the activation and recruitment of B cells producing IgE,
mast cells and eospinophils. The higher IL-4 levels observed in
sarcoidosis may therefore also account for the peripheral antibody
response which is stronger than that seen in tuberculosis [29].
Elevated serum IL-4 in sarcoidosis suggests that the use of selective
IL-4 antagonists or soluble recombinant IL-4 receptors could be
investigated for their efficacy to reduce disease activity in
sarcoidosis [30]. Detailed investigations into peripheral IL-4 levels
in sarcoidosis may also further our understanding into the
mechanisms of action of immunosupressent therapy in the disease.
Our study has several limitations. Firstly, given the inherent
intragroup variability of BAL cytokine levels seen in disease states,
a much larger analysis will be needed to exclude the possibility of
further differences being found between sarcoidosis and BAL
cytokine profiles. This is particularly important for those cytokines
where the median level is low, despite there being a large detected
range e.g. when measuring levels of INFc and IL-8 in the BAL of
sarcoidosis and tuberculosis patients. A larger data set will also be
able to determine the immunological or clinical relevance of any
outliers at the higher range of the cytokine measurement. As part
of a larger study, it would be interesting to include patients with
other granulomatous diseases such as Wegener’s granulomatosis.
This could determine whether there is a cytokine profile that
reflects granulomatous lung conditions in general. Secondly, the
stage of disease (as determined by pulmonary radiograph) in
patients with sarcoidosis was not determined for this study as our
experience has shown us that even expert radiologists can make
subjectively differing assessments of stage when assessing the same
radiographs. However, presence or absence of pulmonary fibrosis
through High Resolution CT scanning of the chest was not
associated with BAL or serum cytokine profile in sarcoidosis (data
not shown). Finally, all BAL samples were taken from patients in
the acute stage of their disease prior to commencing appropriate
therapy but sera were taken from patients with a longer disease
duration, some of whom were on treatment. Despite minimal
maintenance doses of immunosuppression, we cannot exclude the
possibility that even low doses may have affected the cytokine
profile.
However, a comparison of patients with acute untreated
pulmonary sarcoidosis (n = 16) and those with more chronic
Figure 3. Partial Least Squares is used to create a linear regression model to accurately discriminate between sarcoidosis and
tuberculosis sera.
doi:10.1371/journal.pone.0038083.g003
Sarcoidosis and Tuberculosis Cytokine Profiles
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e38083
Sarcoidosis and Tuberculosis Cytokine Profiles
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e38083
disease (n = 24), some of whom may have been on steroid therapy,
shows that there were no differences in any serum cytokine
measured, indicating no significant effect of immunosuppression
on the serum cytokine profile in sarcoidosis (data not shown).
Furthermore, the main difference we identified between saroci-
dosis and tuberculosis, ie serum IL-4 levels, remains statistically
significant after correction for multiple comparisons even when
only patients with acute untreated pulmonary sarcoidosis and
active pulmonary tuberculosis were compared (figure 2c). All these
samples were taken from patients at the time of bronchoscopy,
prior to starting treatment for either tuberculosis or sarcoidosis.
The significant difference in serum IL-4 levels between the two
diseases is therefore not an artifact of treatment.
There are currently no consistently reliable blood tests to either
diagnose sarcoidosis or to distinguish between sarcoidosis and
tuberculosis. Serum Angiotensin Converting Enzyme (ACE) levels
measured in sarcoidosis to monitor disease progression (which are
the only serum biomarker in routine clinical use) are non-specific
as ACE is elevated in a number of diseases including tuberculosis
itself [31]. After analysis of a broad spectrum of immune
biomarkers (including Th1, Th2 and granuloma-associated
cytokines) in both BAL and serum, we have shown for the first
time that only one cytokine in one compartment, serum IL-4, is
significantly different between sarcoidosis and tuberculosis and
that this difference holds up under strict statistical correction for
multiple comparisons. We have also shown that this difference is
still present when analysing patients at first presentation with acute
pulmonary disease, prior to any treatment, as would be found in
the clinical setting where rapid and accurate diagnosis is
paramount.
Despite these findings, the single measurement of serum IL-4
will not suffice for differential diagnosis between diseases. Despite
the differences being statistically significant, there is still consid-
erable overlap between the levels measured in individual patients
with sarcoidosis and tuberculosis. However, the differences seen
with IL-4 may form the basis of a broader serum cytokine profile
to accurately distinguish sarcoidosis from tuberculosis; incorpo-
rating additional markers in a larger study might substantially
improve on the 73% accuracy of the panel used here. Such future
studies should focus only on newly diagnosed tuberculosis and
sarcoidosis patients in the acute stage of disease, prior to starting
any therapy, as these groups are where disease differentiation is
paramount. Such an approach may prove a rapid adjunct to
differential diagnosis which could be employed in the clinical
setting prior to any invasive procedures. Furthermore, systemic
Th2 cytokine differences between the two diseases may underpin
different disease outcomes in patients exposed to similar respira-
tory stimuli.
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